Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2019.10595

OL-0-0-10595

Articles

Expression of programmed cell death-ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study

Zhu

Dongdong

1 * Zhu

Jun

1 * Yu

Wei

1 * Hong

Peng

1 Fan

1 Zhang

Zhongyuan

1 Li

Jun

2 He

Qun

2 Han

Wenke

1 Shen

Cheng

1 Jin

Jie

1Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, P.R. China 2Department of Pathology, Peking University First Hospital, Beijing 100034, P.R. China

Correspondence to: Dr Cheng Shen or Dr Jie Jin, Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, 8 Xishiku Street, Xicheng, Beijing 100034, P.R. China, E-mail: shencheng@263.net, E-mail: 18810534177@163.com *

Contributed equally

09 2019

09 07 2019

18 3 2670 2676 14092018 17052019

2019

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study evaluated programmed cell death-ligand 1 (PD-L1) expression in tumor cells and in the tumor microenvironment (TME) and its association with clinical data in primary testicular diffuse large B cell lymphoma (DLBCL). PD-L1 was determined by immunohistochemistry in 30 patients with primary testicular DLBCL and assessed for associations with clinical characteristics, progression-free survival (PFS) and overall survival (OS). The mean patient age was 62.2 years. Overall, 10 (33.3%) patients had advanced-stage (stage III/IV) disease and 14 (46.7%) patients had an International Prognostic Index (IPI) of ≥3. The median follow-up time following orchiectomy was 23.5 months. During this time, 10 (33.3%) patients experienced disease progression and 11 (36.7%) patients succumbed. PD-L1 expression in tumor cells and in the TME was detected in 20 (66.7%) and 13 (43.3%) patients, respectively. PD-L1 expression on tumor cells and in the TME was higher in those at an early stage compared with patients with an advanced stage of disease (P=0.045 and 0.017, respectively). In addition, PD-L1 expression in tumor cells was higher in patients with a low IPI compared with those with a high IPI (P=0.019). A Kaplan-Meier analysis identified no association of PD-L1 expression on tumor cells with PFS (P=0.763) or OS (P=0.531), or of PD-L1 expression in the TME with PFS (P=0.572) or OS (P=0.934). The present study demonstrated that PD-L1 expression in tumor cells and in the TME was higher in patients at an early stage of disease compared with those at an advanced stage, and that PD-L1 expression on tumor cells was higher in patients with a low IPI than in those with a high IPI. Furthermore, PD-L1 expression in tumor cells and in the TME was not associated with PFS or OS.

primary testicular lymphoma primary testicular diffuse large B cell lymphoma programmed cell death-ligand 1

Introduction

Primary testicular lymphoma (PTL) is an uncommon and aggressive form of extranodal non-Hodgkin lymphoma (NHL) (1). PTL is the most common testicular malignancy in men >60 years of age (2). PTL accounts for <5% of testicular malignancies and 1–2% of NHL (3). Overall, 60–79% of patients present with an early stage of disease (stage I/II), but the outcome is poor (4). In recent years, immunotherapy has become a promising and effective treatment strategy for several types of malignancy.

Programmed cell death-ligand 1 (PD-L1), also known as B7-H1 or CD274, is an inhibitory ligand of programmed cell death 1 (PD-1). PD-L1 is expressed on the surface of tumor cells, T cells and other immune cells (5,6). The binding of PD-L1 to PD-1 suppresses the activation and effector function of T cells, thereby inducing T-cell exhaustion and functioning as a crucial checkpoint in the regulation of cellular and humoral immune responses (7–9). Targeting the PD-1/PD-L1 signaling pathway has marked clinical therapeutic efficacy, not only in solid tumors (10) but also in Hodgkin lymphoma and NHL (11,12).

PTL, characterized by tumors arising in an immune-privileged site and under the selective pressure of immune surveillance, may develop an immune escape phenotype (13). Furthermore, a nascent PTL clone may benefit from developing in an immune-privileged site behind the blood-testis barrier (14). Genetic alterations in 9p24.1, resulting in increased expression of PD-L1, have been demonstrated in PTL (15). Diffuse large B cell lymphoma (DLBCL), the predominant histopathological type of PTL, accounts for 80–98% of PTL cases (16). Previous studies have reported the expression of PD-L1 in DLBCL (17,18); however, studies of PD-L1 expression in primary testicular DLBCL (PT-DLBCL) are lacking. In the present study, the expression of PD-L1 in PT-DLBCL was investigated retrospectively. Using a well-annotated cohort of patients, the immunohistochemical expression of PD-L1 on tumor cells and in the tumor microenvironment (TME) was evaluated, and its association with clinical data was analyzed.

Materials and methods <sec> <title>Patients and samples

In total, 30 patients, aged 33–66 years, were diagnosed with PT-DLBCL at Peking University First Hospital (Beijing, China) between August 2006 and July 2017, and were included in the present study. Patients with clear pathological diagnosis and complete clinical data were included in the study, and patients whose pathological diagnosis was not PT-DLBCL and whose clinical data were incomplete were excluded. All patients underwent orchiectomy for pathological diagnosis. Formalin-fixed paraffin-embedded blocks from 30 PT-DLBCL specimens were retrieved from the Department of Urological Pathology, Peking University First Hospital. Clinicopathological and follow-up data were collected and entered into a database. The Ann Arbor staging classification system was used for staging, and the International Prognostic Index (IPI) was used for risk stratification (14). The algorithm of Hans et al (19) was used to determine germinal center or non-germinal center classification. Immunohistochemistry was used to determine the expression of B cell leukemia 2 (BCL-2). BCL-2 expression was assessed by BCL-2 score. The scoring criteria were: 0 points (no lymphoma cells stained); 1 point (1–10% stained lymphoma cells); 2 points (11–30%); 3 points (31–70%); and 4 points (>70%) (20). Pathologists determined the BCl-2 score as part of the postoperative pathology to determine PT-DLBCL diagnosis, and the BCL-2 scores were collected from postoperative pathology reports of the patients. Overall survival (OS) was calculated from the time of diagnosis to the time of mortality or the last follow-up. Progression-free survival (PFS) was calculated from the time of diagnosis to the time of disease progression, mortality or the last follow-up. The study was approved by the Ethics Committee of Peking University First Hospital [(Beijing, China); ethics no., 2018 (197)]. A waiver of written informed consent was granted from the Ethics Committee of Peking University First Hospital, since the study was a retrospective analysis of routine data.

Immunohistochemistry

All tumor specimens were acquired by orchiectomy prior to chemotherapy and radiotherapy (RT). The expression of PD-L1 in the PT-DLBCL samples was evaluated according to standard immunohistochemistry protocols. Briefly, 4 µm-thick sections from formalin-fixed paraffin-embedded specimens were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol (100, 95, 95 and 85%) and washed in distilled water. Heat-induced antigen retrieval at 120°C for 20 min was performed with Tris-EDTA buffer (pH 8.0). Following the use of 3% hydrogen peroxidase to block endogenous peroxidase, sections were incubated with 10% normal blocking serum in Tris-buffered saline at room temperature for 20 min. The sections were then incubated with anti-human PD-L1 rabbit monoclonal antibody (1:50; E1L3N; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C for 16 h, followed by incubation with the secondary antibody (goat anti-rabbit IgG/HRP polymer; PV-6001; OriGene Technologies, Inc., Beijing, China) at 37°C for 40 min. Next, the sections were counterstained with hematoxylin at room temperature for 3 min, dehydrated, covered with a coverslip and viewed under a light microscope (magnification, ×40).

A total of two independent pathologists assessed the expression of PD-L1 on tumor cells and the expression of PD-L1 in the TME, without any prior knowledge of the clinical data of this cohort.

Positive PD-L1 expression on tumor cells was defined as ≥5% of lymphoma cells exhibiting distinct membranous and/or cytoplasmic staining for PD-L1, regardless of the PD-L1-positivity of nonmalignant stromal cells. Positive PD-L1 expression in the TME was defined as positive staining of stromal cells representing ≥20% of the total tissue (18).

Statistical analysis

The experiment was repeated 3 times. The data were expressed as the mean ± standard deviation or n (%) as appropriate. Patients were divided into subgroups according to the expression of PD-L1 on tumor cells or the expression of PD-L1 in the TME (positive or negative). The association of PD-L1 expression with clinicopathological characteristics was examined using Fisher's exact test. Survival curves for OS and PFS were prepared using the Kaplan-Meier method and analyzed using the log-rank test. SPSS software (version 14.0; SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis of all data, and P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Patient characteristics

The demographic and clinicopathological characteristics are presented in Table I. The study included 30 patients with a mean age of 62.2±15.0 years (range, 33–66 years). Of these patients, 14 (46.7%) had PTL in the left testicle, 12 (40.0%) patients had PTL in the right testicle and 4 (13.3%) patients had PTL in both testicles. Lactate dehydrogenase (LDH) was assessed in 21 patients, and 6 (28.6%) had increased levels; β₂-microglobulin (β2-MG) was assessed in 13 patients, and 5 (38.5%) had increased levels; 4 (13.3%) of the 30 patients had B symptoms, including unexplained fever, drenching night sweats and weight loss >10% of normal body weight; 10 (33.3%) had advanced-stage (stage III/IV) disease; and 14 (46.7%) had an IPI ≥3. Inguinal orchiectomy was performed as a diagnostic procedure and initial treatment, and DLBCL was confirmed in all 30 patients following histopathological examination. Of 19 patients that were assessed for subtype, nine (47.4%) had germinal center B cell-like (GCB) subtype disease and 10 (52.6%) had non-GCB subtype disease. BCL-2 expression was assessed in 15 patients, with scores of 2–3 in 6 (40.0%) patients.

Treatments and outcomes

The final follow-up date was July 2018. The median follow-up time following orchiectomy was 23.5 months (range, 2–143 months). Disease progression occurred in 10 (33.3%) patients; among these patients, one experienced central nervous system (CNS) relapse, and one experienced contralateral testis relapse. Overall, 11 (36.7%) patients succumbed. Following orchiectomy, 23 (76.7%) patients received chemotherapy, including a doxorubicin-containing regimen in all 23 patients and a rituximab-containing regimen in 15 patients. The median number of cycles was 6 (range, 1–8). A total of 11 patients received RT; 9 of these received RT at the contralateral testis alone, and 2 received RT at the contralateral testis and the abdominal lymph nodes. A total of 18 patients received CNS prophylaxis. In total, 10 patients received multimodal therapy (surgery+chemotherapy+radiotherapy+CNS prophylaxis) (Table II).

PD-L1 expression on tumor cells and in the TME

Among the 30 patients with PT-DLBCL, positive PD-L1 expression on tumor cells was detected in 20 (66.7%), and a lack of PD-L1 expression on tumor cells was detected in 10 (33.3%). Positive PD-L1 expression in the TME was detected in 13 patients (43.3%), and a lack of PD-L1 expression in the TME was detected in 10 patients (56.7%; Fig. 1). Among the 19 patients assessed for subtype, positive PD-L1 expression on tumor cells was detected in 5 (55.6%) with the GCB subtype, and a lack of PD-L1 expression on tumor cells was detected in 4 (44.4%) with the GCB subtype. Positive PD-L1 expression in the TME was detected in 3 patients (33.3%) with the GCB subtype, and a lack of PD-L1 expression in the TME was detected in 6 patients (66.7%) with the GCB subtype. Positive PD-L1 expression on tumor cells was detected in 8 patients (80.0%) with the non-GCB subtype, and a lack of PD-L1 expression on tumor cells was detected in 2 patients (20.0%) with the non-GCB subtype. Positive PD-L1 expression in the TME was detected in 5 patients (50.0%) with the non-GCB subtype, and a lack of PD-L1 expression in the TME was detected in 5 patients (50.0%) with the non-GCB subtype (Fig. 2).

Association of PD-L1 expression with clinicopathological characteristics

Overall, early-stage (stage I/II) and advanced-stage (stage III/IV) disease was identified in 20 (66.7%) and 10 (33.3%) patients, respectively. PD-L1 expression on tumor cells was significantly higher in patients at an early stage compared with those at an advanced stage (16/20, 80.0% vs. 4/10, 40.0%; P=0.045), and there was a significant difference in PD-L1 expression in the TME between these two groups (60.0 vs. 10.0%; P=0.017). IPIs <3 and ≥3 were identified in 16 (53.3%) and 14 (46.7%) patients, respectively. PD-L1 expression on tumor cells was significantly higher in patients with an IPI <3 compared with patients with an IPI ≥3 (87.5 vs. 42.9%; P=0.019); however, there was no significant difference in PD-L1 expression in the TME between these two groups (50.0 vs. 35.7%; P=0.484). According to the postoperative pathological results, 9 (47.4%) patients had a GCB subtype, and 10 (52.6%) patients had a non-GCB subtype. No significant differences were observed between the subtypes in terms of PD-L1 expression on tumor cells or in the TME (P=0.35 and 0.65, respectively). In addition, age, laterality, B symptoms, LDH level, β2-MG level and BCL-2 expression were not significantly associated with PD-L1 expression on either tumor cells or in the TME (Table III).

Association of PD-L1 expression with PFS and OS

The median follow-up time after orchiectomy was 23.5 months (range, 2–143 months). During this time, 10 (33.3%) patients experienced disease progression, and 11 (36.7%) patients succumbed. A Kaplan-Meier analysis indicated that PD-L1 expression on tumor cells was not associated with PFS (P=0.763) or OS (P=0.531; Fig. 3A and B) and that PD-L1 expression in the TME was not associated with PFS (P=0.572) or OS (P=0.934; Fig. 3C and D). Following division of the patients into subgroups (GCB subtype and non-GCB subtype), a Kaplan-Meier analysis revealed that PD-L1 expression was not associated with PFS or OS in the GCB subtype subgroup or in the non-GCB subtype subgroup (Fig. S1). Following division of the patients into subgroups according to BCL-2 expression, a Kaplan-Meier analysis also revealed that PD-L1 expression was not associated with PFS or OS in the subgroups with BCL-2 expression scores of 0–1 and BCL-2 expression scores of 2–3 (Fig. S2). However, the Kaplan-Meier analysis demonstrated that an early stage of disease was associated with longer PFS (P=0.019) and OS (P=0.016; Fig. 3E and F). In the multivariate Cox model adjusting for clinical stage, PD-L1 expression on tumor cells or in the TME was not an independent risk factor for PFS or OS.

Discussion

Previous studies have demonstrated that PD-L1 is expressed in various types of cancer, including DLBCL, and correlates with both favorable and unfavorable prognoses (21,22). In a previous study on DLBCL, PD-L1 expression on tumor cells or in the TME was reported to correlate with pathological tumor stage, grade and prognosis (17). DLBCL is the predominant histopathological type of PTL, and PD-L1 overexpression in DLBCL has been reported previously (23). Therefore, whether the clinical significance of PD-L1 expression in DLBCL can be equally applied in PT-DLBCL remains unknown and warrants further study. To the best of our knowledge, the present study is the first to investigate the association of PD-L1 expression with clinicopathological characteristics and oncological outcomes in patients with PT-DLBCL. PD-L1 can be expressed on both tumor cells and tumor-infiltrating immune cells (24). PD-L1 expression is induced endogenously by genetic aberrations or oncogenic signaling, and exogenously by cytokines secreted by immune cells (25). However, the underlying molecular mechanism of PD-L1 expression in PT-DLBCL is unclear and requires further investigation.

Of particular note is the threshold for identifying PD-L1 positivity, which has varied widely. In the present study, 5% was used as the cut-off for PD-L1 positivity on tumor cells, and 20% as the cut-off for PD-L1 positivity in the TME, in accordance with a previous study (18). Among the 30 patients with PT-DLBCL included in the present study, 67% patients were positive for PD-L1 on tumor cells and 43% were positive for PD-L1 in the TME. To put these results into context, they were compared with those of published studies concerning PD-L1 expression in DLBCL. According to the reviewed literature, the expression rates of PD-L1 on tumor cells and in the TME fluctuated from 26 to 75% and from 30 to 66%, respectively (26,27). The results from the present study were comparable with those observed in previous studies. Several studies have investigated the expression of PD-L1 in DLBCL using other standards. Kiyasu et al (17) reported that the rates of positive PD-L1 expression on tumor cells and in the TME were 10.5 and 15.3% using thresholds of 30.0 and 20.0%, respectively. Xing et al (28) reported that the rates of positive PD-L1 expression on tumor cells and in the TME were 16.0 and 27.0% using thresholds of 30.0 and 5.0%, respectively. The higher rates of PD-L1 expression in our cohorts may be due to the nature of testicles as immunologically privileged sites, or to differences in race, sample size, antibody type, immunohistochemical detection system and experimental standards.

The results of the present study indicated that patients with an early stage of disease (stage I/II) presented with higher PD-L1 expression on tumor cells compared with those at an advanced stage (stage III/IV). The results also indicated that patients at an early (stage I/II) presented with higher PD-L1 expression in the TME than those at an advanced stage (stage III/IV). Furthermore, it was observed that patients with a low IPI presented with higher PD-L1 expression on tumor cells compared with those with a high IPI. However, no significant differences were observed in PD-L1 expression on tumor cells or in the TME between subtypes. Pollari et al (27) reported that patients with PTL with limited stage I–II disease presented with higher PD-L1 expression in the TME compared with those with advanced stage III–IV disease. Pollari et al (27) also described how PD-L1 is also expressed on tumor-infiltrating non-malignant cells, primarily macrophages, and PD-1 is expressed on tumor-infiltrating lymphocytes (TILs). The interaction of PD-L1⁺ macrophages and PD-1⁺ TILs may modify the TME and promote an antitumor immune response. Ishii et al (21) reported that the high expression of PD-L1 on tumor cells was correlated with an early disease stage in patients with small cell lung cancer. However, the majority of studies concerning PD-L1 expression have revealed that PD-L1 expression on tumor cells is associated with an unfavorable prognosis (17,18,22). The mechanism is as follows: The PD-L1 expression on tumor cells can lead to T-cell exhaustion and a state of non-responsiveness, and can enable tumor cells to escape the immune response (29,30). In PT-DLBCL, there are PD-L1-positive tumor cells, PD-L1-positive macrophages and PD-1-positive TILs, indicating that the PD-1/PD-L1 signaling pathway is much more complex (27). Nevertheless, the mechanism underlying the reciprocal effects remains unclear and requires further investigation.

To date, studies on the prognostic impact of PD-L1 expression in DLBCL have concentrated on forms of the disease other than PTL. Kiyasu et al (17) were the first to report that PD-L1 expression on tumor cells is associated with a shorter OS in patients with DLBCL. Hu et al (18) reported that PD-L1 expression predicts poor survival in patients with DLBCL in China. However, the present study did not identify that PD-L1 expression in tumor cells or in the TME was associated with PFS or OS in patients with PT-DLBCL.

There are several limitations to the present study. First, this was a single-center retrospective study with a small sample size of 30 patients; therefore, prospective studies with more patients are warranted to validate the status and prognostic value of PD-L1 expression in patients with PT-DLBCL. Secondly, immunohistochemistry is a semiquantitative technique and is influenced by multiple factors, such as antibody concentrations and cut-off criteria. However, positive and negative control slides were used in the present study to ensure the reliability of the protocol used. Thirdly, because the ideal treatment for PTL-DLBCL remains under debate, the patients in the present study received a variety of treatments, which made it difficult to identify relevant prognostic factors.

In conclusion, PD-L1 is differentially expressed in tumor cells and in the TME in PT-DLBCL. No significant association was identified with age, laterality, B symptoms, LDH, β2-MG, GCB subtype or BCL-2 expression. However, PD-L1 expression in tumor cells and in the TME was higher in patients at an early stage of disease compared with in those at an advanced stage, and PD-L1 expression on tumor cells was higher in patients with a low IPI compared with those with a high IPI. Furthermore, PD-L1 expression on tumor cells and in the TME was not associated with PFS or OS.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

CS, WY and JJ designed the study and revised the manuscript. DDZ, JZ and PH contributed to the writing of the manuscript and analyzing the patient data. YF contributed to the collection and analysis of the data. JL and QH contributed to the assessment of PD-L1 expression. WKH and ZYZ designed the study and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Peking University First Hospital (ethics no., 2018 [197]). A waiver of written informed consent was granted from the Ethics Committee of Peking University First Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

BCL-2

B cell leukemia 2

β2-MG

β₂-microglobulin

CNS

central nervous system

DLBCL

diffuse large B cell lymphoma

GCB

germinal center B cell-like

IPI

International Prognostic Index

LDH

lactate dehydrogenase

NHL

non-Hodgkin lymphoma

non-GCB

non-germinal center B cell-like

overall survival

PD-1

programmed cell death 1

PD-L1

programmed cell death-ligand 1

PFS

progression-free survival

PT-DLBCL

primary testicular DLBCL

PTL

primary testicular lymphoma

radiotherapy

TME

tumor microenvironment

References 1

Kemal

Teker

Demirag

Yucel

Primary testicular lymphoma: A single centre experience

Exp Oncol372232262015

10.31768/2312-8852.2015.37(3):223-226

26422109

Vitolo

Ferreri

Zucca

Primary testicular lymphoma

Crit Rev Oncol Hematol651831892008

10.1016/j.critrevonc.2007.08.005

17962036

Møller

d'Amore

Christensen

Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis The Danish Lymphoma Study Group, LYFO

Eur J Cancer 30A176017641994

10.1016/0959-8049(94)00311-R

Zucca

Conconi

Mughal

Sarris

Seymour

Vitolo

Klasa

Ozsahin

Mead

Gianni

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group

J Clin Oncol2120272003

10.1200/JCO.2003.11.141

12506165

Dong

Sun

Zhang

PD-1 and its ligands are important immune checkpoints in cancer

Oncotarget8217121862017

27974689

Goodman

Patel

Kurzrock

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

Nat Rev Clin Oncol142032202017

10.1038/nrclinonc.2016.168

27805626

Chen

Chapuy

Ouyang

Sun

Roemer

Fletcher

Freeman

Shipp

Rodig

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

Clin Cancer Res19346234732013

10.1158/1078-0432.CCR-13-0855

23674495

Francisco

Sage

Sharpe

The PD-1 pathway in tolerance and autoimmunity

Immunol Rev2362192422010

10.1111/j.1600-065X.2010.00923.x

20636820

Freeman

Long

Iwai

Bourque

Chernova

Nishimura

Fitz

Malenkovich

Okazaki

Byrne

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

J Exp Med192102710342000

10.1084/jem.192.7.1027

11015443

Topalian

Hodi

Brahmer

Gettinger

Smith

McDermott

Powderly

Carvajal

Sosman

Atkins

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

N Engl J Med366244324542012

10.1056/NEJMoa1200690

22658127

Bachy

Coiffier

Anti-PD1 antibody: A new approach to treatment of lymphomas

Lancet Oncol15782014

10.1016/S1470-2045(13)70587-4

24332517

Ansell

Lesokhin

Borrello

Halwani

Scott

Gutierrez

Schuster

Millenson

Cattry

Freeman

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

N Engl J Med3723113192015

10.1056/NEJMoa1411087

25482239

Dunn

Bruce

Ikeda

Old

Schreiber

Cancer immunoediting: From immunosurveillance to tumor escape

Nat Immunol39919982002

10.1038/ni1102-991

12407406

Cheah

Wirth

Seymour

Primary testicular lymphoma

Blood1234864932014

10.1182/blood-2013-10-530659

24282217

Merryman

Armand

Wright

Rodig

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Blood Adv1264326542017

29296917

Menter

Ernst

Drachneris

Dirnhofer

Barghorn

Went

Tzankov

Phenotype profiling of primary testicular diffuse large B-cell lymphomas

Hematol Oncol3272812014

10.1002/hon.2090

23949965

Kiyasu

Miyoshi

Hirata

Arakawa

Ichikawa

Niino

Sugita

Yufu

Choi

Abe

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

Blood126219322012015

10.1182/blood-2015-02-629600

26239088

Rao

Chen

Lai

Huang

Jiang

Lin

Xia

Cai

Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: A retrospective study

Chin J Cancer36942017

10.1186/s40880-017-0262-z

29246182

Hans

Weisenburger

Greiner

Gascoyne

Delabie

Ott

Müller-Hermelink

Campo

Braziel

Jaffe

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Blood1032752822004

10.1182/blood-2003-05-1545

14504078

Gascoyne

Adomat

Krajewski

Krajewska

Horsman

Tolcher

O'Reilly

Hoskins

Coldman

Reed

Connors

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Blood902442511997

9207459

Ishii

Azuma

Kawahara

Yamada

Imamura

Tokito

Kinoshita

Kage

Hoshino

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer

J Thorac Oncol104264302015

10.1097/JTO.0000000000000414

25384063

Zhang

Feng

Zhao

Fan

Meng

Cui

Zhang

Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma

Med Oncol34942017

10.1007/s12032-017-0941-2

28409437

Georgiou

Chen

Berglund

Ren

de Miranda

Lisboa

Fangazio

Zhu

Hou

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Blood127302630342016

10.1182/blood-2015-12-686550

27030389

Andorsky

Yamada

Said

Pinkus

Betting

Timmerman

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

Clin Cancer Res17423242442011

10.1158/1078-0432.CCR-10-2660

21540239

Kwon

Kim

Nam

Paik

Kim

Heo

Kim

Jeon

Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas

Histopathology68107910892016

10.1111/his.12882

26426431

Xu-Monette

Zhou

Young

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Blood13168832018

29118007

Pollari

Brück

Pellinen

Vähämurto

Karjalainen-Lindsberg

Mannisto

Kallioniemi

Kellokumpu-Lehtinen

Mustjoki

Leivonen

Leppä

PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma

Haematologica103190819142018

10.3324/haematol.2018.197194

30026337

Xing

Dresser

Zhang

Evens

Woda

Chen

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications

Oncotarget759976599862016

10.18632/oncotarget.11045

27527850

Wherry

Kurachi

Molecular and cellular insights into T cell exhaustion

Nat Rev Immunol154864992015

10.1038/nri3862

26205583

Pauken

Wherry

Overcoming T cell exhaustion in infection and cancer

Trends Immunol362652762015

10.1016/j.it.2015.02.008

25797516

Figure 1.

Immunohistochemical staining of PD-L1. (A) Positive expression and (B) lack of expression of PD-L1 in tumor cells; (C) positive expression and (D) lack of expression of PD-L1 in the TME. Magnification, ×40. PD-L1, programmed cell death ligand-1; TME, tumor microenvironment.

Figure 2.

Immunohistochemical staining of PD-L1. (A) Positive expression and (B) lack of expression of PD-L1 in tumor cells in patients with the GCB subtype. (C) Positive expression and (D) lack of expression of PD-L1 in the TME in patients with the GCB subtype. (E) Positive expression and (F) lack of expression of PD-L1 in tumor cells in patients with the non-GCB subtype. (G) Positive expression and (H) lack of expression of PD-L1 in the TME in patients with the non-GCB subtype. Magnification, ×40. PD-L1, programmed cell death ligand-1; TME, tumor microenvironment; GCB, germinal center B cell-like; non-GCB, non-germinal center B cell-like.

Figure 3.

Association of PD-L1 expression with PFS and OS. (A) Association between PD-L1 expression on tumor cells and PFS in patients with PT-DLBCL. (B) Association between PD-L1 expression on tumor cells and OS in patients with PT-DLBCL. (C) Association between PD-L1 expression in the TME and PFS in patients with PT-DLBCL. (D) Association between PD-L1 expression in the TME and OS in patients with PT-DLBCL. (E) Association between clinical stage and PFS in patients with PT-DLBCL. (F) Association between clinical stage and OS in patients with PT-DLBCL. PFS, progression free survival; PT-DLBCL, primary testicular-diffuse large B cell lymphoma; OS, overall survival; TME, tumor microenvironment; PD-L1, programmed cell death ligand-1.

Table I.

Demographic and clinicopathological characteristics of 30 patients with primary testicular diffuse large B cell lymphoma.

Variable	n (%)
Age, years
≤60	12 (40.0)
>60	18 (60.0)
Laterality
Left	14 (46.7)
Right	12 (40.0)
Bilateral	4 (13.3)
LDH^a, U/l
≤245	15 (71.4)
>245	6 (28.6)
β2-MG^b, mg/l
≤2.52	8 (61.5)
>2.52	5 (38.5)
Clinical stage
I–II	20 (66.7)
III–IV	10 (33.3)
IPI
<3	16 (53.3)
≥3	14 (46.7)
GCB subtype^c
Non-GCB	10 (52.6)
GCB	9 (47.4)
BCL-2 scored
0-1	9 (60.0)
2-3	6 (40.0)

The data of 9 patients were missing

the data of 17 patients were missing

the data of 11 patients were missing; dthe data of 15 patients were missing. LDH, lactate dehydrogenase; β2-MG, β₂-microglobulin; GCB, germinal center B cell-like; BCL-2, B cell leukemia 2; IPI, International Prognostic Index.

Table II.

Treatments and outcomes of 30 patients with primary testicular diffuse large B cell lymphoma.

Variable	n (%)
Chemotherapy
No	7 (23.3)
Yes	23 (76.7)
Rituximab^a
No	8 (34.8)
Yes	15 (65.2)
Radiotherapy
No	19 (63.3)
Yes	11 (36.7)
CNS prophylaxis
No	12 (40.0)
Yes	18 (60.0)
Multimodal therapy (surgery+chemotherapy+radiotherapy+CNS prophylaxis)
No	20 (66.7)
Yes	10 (33.3)
Disease progression
No	20 (66.7)
Yes	10 (33.3)
Mortality
No	19 (63.3)
Yes	11 (36.7)

n=23 (patients who had received chemotherapy). CNS, central nervous system.

Table III.

Association between PD-L1 expression and clinicopathological characteristics in 30 patients with primary testicular diffuse large B cell lymphoma.

	PD-L1 expression in tumor cells, n			PD-L1 expression in tumor microenvironment, n

Features	Negative	Positive	P-value	Negative	Positive	P-value
Age, years			0.694			>0.999
≤60	3	9		7	5
>60	7	11		10	8
Laterality			0.127			0.733
Left	7	7		9	5
Right	3	9		6	6
Bilateral	0	4		2	2
B symptoms			0.584			0.113
No	8	18		13	13
Yes	2	2		4	0
LDH^a, U/l			0.262			>0.999
≤245	5	10		7	8
>245	0	6		3	3
β2-MG^b, mg/l			>0.999			>0.999
≤2.52	2	6		4	4
>2.52	2	3		3	2
Clinical stage			0.045			0.017
I–II	4	16		8	12
III–IV	6	4		9	1
IPI			0.019			0.484
<3	2	14		8	8
≥3	8	6		9	5
GCB subtype^c			0.35			0.650
Non-GCB	2	8		5	5
GCB	4	5		6	3
BCL-2 score^d			>0.999			0.315
0-1	3	6		3	6
2-3	2	4		4	2

The data of 9 patients were missing

the data of 17 patients were missing

the data of 11 patients were missing

the data of 15 patients were missing. PT-DLBCL, primary testicular diffuse large B cell lymphoma; LDH, lactate dehydrogenase; β2-MG, β₂-microglobulin; GCB, germinal center B cell-like; BCL-2, B cell leukemia 2; IPI, International Prognostic Index. B symptoms were defined as unexplained fever, drenching night sweats and weight loss >10% of normal body weight.